COZADD BRUCE C 4
4 · Jazz Pharmaceuticals plc · Filed Dec 1, 2025
Insider Transaction Report
Form 4
COZADD BRUCE C
Director
Transactions
- Exercise/Conversion
Ordinary Shares
2025-11-26$123.36/sh+76,689$9,460,355→ 470,021 total - Exercise/Conversion
Ordinary Shares
2025-11-26$123.36/sh+811$100,045→ 470,832 total - Sale
Ordinary Shares
2025-11-26$178.06/sh−30,487$5,428,567→ 440,345 total - Sale
Ordinary Shares
2025-11-26$179.23/sh−8,380$1,501,943→ 431,965 total - Sale
Ordinary Shares
2025-11-26$179.79/sh−507$91,155→ 431,458 total - Sale
Ordinary Shares
2025-11-26$177.27/sh−38,126$6,758,672→ 393,332 total - Exercise/Conversion
Incentive Stock Option (right to buy)
2025-11-26−811→ 0 totalExercise: $123.36Exp: 2026-02-24→ Ordinary Shares (811 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-26−76,689→ 0 totalExercise: $123.36Exp: 2026-02-24→ Ordinary Shares (76,689 underlying)
Footnotes (5)
- [F1]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $177.70 to $178.685. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F2]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $178.72 to $179.705. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F3]Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $179.73 to $179.96. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F4]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.70 to $177.69. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F5]These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.